<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04291612</url>
  </required_header>
  <id_info>
    <org_study_id>20-067</org_study_id>
    <nct_id>NCT04291612</nct_id>
  </id_info>
  <brief_title>Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease</brief_title>
  <official_title>SEntinel Lymph Node Endometrial Cancer Trial: A Prospective Multicenter International Single-Arm Observational Trial (SELECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out how often endometrial cancer recurs after the standard&#xD;
      treatment as well as how often the standard treatment results in a lymphedema.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2020</start_date>
  <completion_date type="Anticipated">February 26, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 26, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of pelvic/non-vaginal recurrence at 36 months</measure>
    <time_frame>36 months</time_frame>
    <description>Participants will be assessed every 6 (+/- 2) months for 36 months through routine physical examination</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Endometrioid Adenocarcinoma</condition>
  <condition>Endometrial Cancer Stage I</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <description>Participants will have endometrioid adenocarcinoma histological diagnosis with planned surgical treatment including hysterectomy in combination with SLN biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <description>Participants will have undergone surgery and bilateral sentinel lymph node mapping (negative for malignancy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical exam</intervention_name>
    <description>Part 2 participants will be prospectively followed clinically for relapse for 30 months from the date of surgery for physical examination at post-ops visits.</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Potential research subjects will be identified by a member of the patient's treatment team,&#xD;
        the protocol investigator, or a member of the research teams. If the investigator is a&#xD;
        member of the treatment team, s/he will screen their patients' medical records for suitable&#xD;
        research study participants and discuss the study and their potential for enrolling in the&#xD;
        research study. Potential subjects contacted by their treating physician will be referred&#xD;
        to the investigator/research staff of the study. The principal investigators may also&#xD;
        screen the medical records of patients with whom they do not have a treatment relationship&#xD;
        for the limited purpose of identifying patients who would be eligible to enroll in the&#xD;
        study, and to record appropriate contact information in order to approach these patients&#xD;
        regarding the possibility of enrolling in the study. Patients identified in this manner&#xD;
        would subsequently be approached for study enrollment after consultation with their&#xD;
        treating physician.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Screening Inclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status 0-1 or KPS ≥ 70%&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Endometrioid adenocarcinoma histologic diagnosis on endometrial biopsy or dilatation&#xD;
             and curettage confirmed at the enrolling institution&#xD;
&#xD;
          -  No evidence of extrauterine disease, or suspicious pelvic lymph nodes, or distant&#xD;
             metastases, or cervical invasion on pre-operative conventional imaging studies (Pelvic&#xD;
             +/- Abdomen CT or MRI or sonogram, or body PET scan) and physical examination (uterine&#xD;
             confined by exam and imaging )&#xD;
&#xD;
          -  Suitable candidate for surgery&#xD;
&#xD;
          -  Planned surgical treatment including hysterectomy in combination with SLN biopsy and a&#xD;
             bilateral salpingo-oophorectomy&#xD;
&#xD;
          -  No history of second primary cancer (invasive or in situ) within the past 5 years, not&#xD;
             including non-melanoma skin cancer&#xD;
&#xD;
          -  Approved and signed informed consent&#xD;
&#xD;
          -  No history of neoadjuvant chemotherapy or radiotherapy for endometrial cancer&#xD;
&#xD;
          -  No history of prior pelvic or abdominal radiotherapy&#xD;
&#xD;
        Screening Exclusion Criteria:&#xD;
&#xD;
          -  Extrauterine disease, or gross lymph node involvement, or cervical invasion suspected&#xD;
             on pre-operative imaging studies and physical examination (disease not uterine&#xD;
             confined clinical stage &gt; I)&#xD;
&#xD;
          -  Contraindication for SLN mapping&#xD;
&#xD;
          -  The planned treatment is not surgery, or the surgical treatment does not include&#xD;
             hysterectomy in combination with SLN biopsy and a bilateral salpingo-oophorectomy&#xD;
&#xD;
        Eligibility Inclusion Criteria&#xD;
&#xD;
        Patients will be classified in the study cohort (part 2; n=182) according to surgical&#xD;
        treatment received, final post hysterectomy and staging pathologic report, and planned&#xD;
        adjuvant treatment. The inclusion criteria are specified below.&#xD;
&#xD;
        Study Cohort (n=182)&#xD;
&#xD;
        A patient will be enrolled in the study cohort if all the following criteria are met:&#xD;
&#xD;
          -  At surgery, the patient must undergo:&#xD;
&#xD;
               -  Hysterectomy&#xD;
&#xD;
               -  Bilateral salpingo-oophorectomy, unless already previously performed&#xD;
&#xD;
               -  Bilateral pelvic SLN mapping (bilateral sentinel nodes are negative for&#xD;
                  malignancy)&#xD;
&#xD;
          -  On the final pathologic report, the patient must have a diagnosis of:&#xD;
&#xD;
               -  Stage I intermediate-risk endometrial endometrioid cancer (Grade 1 or Grade 2&#xD;
                  with ≥ 50% myometrial invasion or Grade 3 with &lt;50% myometrial invasion,&#xD;
                  including non-invasive disease)&#xD;
&#xD;
               -  Negative pelvic peritoneal cytology&#xD;
&#xD;
          -  Adjuvant treatment as recommended by the multidisciplinary team must be as follows:&#xD;
&#xD;
               -  No adjuvant treatment, or&#xD;
&#xD;
               -  Intravaginal radiation only&#xD;
&#xD;
        Eligibility Exclusion Criteria&#xD;
&#xD;
          -  There is intra-operative detection of extra-uterine disease or grossly involved lymph&#xD;
             nodes&#xD;
&#xD;
          -  Presence of any positive pelvic nodes including micrometastasis and isolated tumor&#xD;
             cells (ITC)&#xD;
&#xD;
          -  Hysterectomy is not performed&#xD;
&#xD;
          -  Bilateral salpingo-oophorectomy is not performed, unless already previously performed&#xD;
&#xD;
          -  Failed unilateral or bilateral SLN mapping&#xD;
&#xD;
          -  Patient undergoes a complete unilateral or bilateral pelvic lymphadenectomy&#xD;
&#xD;
          -  Patient undergoes a radical type C hysterectomy&#xD;
&#xD;
          -  Stage IA endometrioid cancer Grade1 or 2 and myometrial invasion &lt;50%&#xD;
&#xD;
          -  Stage IB Grade 3 endometrioid cancer&#xD;
&#xD;
          -  Non-endometrioid histology: Serous, clear cell, carcinosarcoma, undifferentiated, or&#xD;
             de-differentiated histology noted on final hysterectomy pathology&#xD;
&#xD;
          -  Empty unilateral or bilateral sentinel lymph nodal packet(s)&#xD;
&#xD;
          -  Positive peritoneal cytology&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadeem Abu-Rustum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadeem Abu-Rustum, MD</last_name>
    <phone>212-639-7051</phone>
    <email>abu-rusn@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario Leitao, MD</last_name>
    <phone>212-639-3987</phone>
    <email>leitaom@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hartford Healthcare Cancer Institute @ Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Cosin, MD</last_name>
      <phone>860-826-1101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami (Data Collection Only)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Clomovitz, MD</last_name>
      <phone>305-243-2233</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute Baptist Health South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Paul Diaz, MD</last_name>
      <phone>786-596-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ADVENTHEALTH (Data collection only)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Holloway, MD</last_name>
      <phone>407-303-2422</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic (Data Collection and Data Analysis)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Mariani, MD</last_name>
      <email>Mariani.Andrea@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (All protocol activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadeem Abu-Rustum, MD</last_name>
      <phone>212-639-7051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (All protocol activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadeem Abu-Rustum, MD</last_name>
      <phone>212-639-7051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (All protocol activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadeem Abu-Rustum, MD</last_name>
      <phone>212-639-7051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (All Protocol Activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadeem Abu-Rustum, MD</last_name>
      <phone>212-639-7051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (All protocol activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadeem Abu-Rustum, MD</last_name>
      <phone>212-639-7051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadeem Abu-Rustum, MD</last_name>
      <phone>212-639-7051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (All protocol activities)</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadeem Abu-Rustum, MD</last_name>
      <phone>212-639-7051</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Martino, MD</last_name>
      <phone>610-402-3650</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center (Data Collection Only)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pamela Soliman, MD</last_name>
      <phone>713-792-2121</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charles University and General University Hospital (Data Collection Only)</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cibula,, MD</last_name>
      <phone>224967205</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSPEDALE MICHELE E PIETRO (Data Collection Only)</name>
      <address>
        <city>Ferrera</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Buda, MD</last_name>
      <phone>0173 290851</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UNIVERSITY OF MILANO-BICOCCA, ITALY (Data Collection)</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tommaso Grassi, MD</last_name>
      <phone>+39 02 6448 6099</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FONDAZIONE POLICLINICOUNIVERSITARIO A. GEMELLI, ITALY (Data Collection Only)</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Scambia, MD</last_name>
      <phone>39 06 30151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSLO UNIVERSITY HOSPITAL,RIKSHOPITALET (Data Collection Only)</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ane Gerda, MD, PhD</last_name>
      <phone>+47 22 93 44 46</phone>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
  </removed_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrial Cancer</keyword>
  <keyword>Endometrioid Adenocarcinoma</keyword>
  <keyword>20-067</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

